Diagnostic BioMarkers for Fibrotic Disorders

Patent metadata

Field	Value
Publication number	US-2016228509-A9
Application number	US-201313852079-A
Country	US
Kind code	A9
Filing date	Mar 28, 2013
Priority date	May 8, 2009
Publication date	Aug 11, 2016
Grant date	—

Abstract

The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

First claim

1 . A method of inhibiting fibrosis in a cell, comprising contacting said cell with an effective amount of a BMP9 or BMP10 antagonist, thereby inhibiting fibrosis in said cell.

2 . The method of claim 1 , wherein said cell is selected from the group consisting of a pulmonary cell, a liver cell, a kidney cell, a cardiac cell, a musculoskeletal cell, a skin cell, an eye cell, and a pancreatic cell.

3 . A method of treating a fibrotic disorder in a subject, comprising administering to said subject an effective amount of a BMP9 or BMP10 antagonist, thereby treating a fibrotic disorder in said subject.

4 . A method of preventing a fibrotic disorder in a subject, comprising administering to said subject an effective amount of a BMP9 or BMP10 antagonist, thereby preventing a fibrotic disorder in said subject.

5 . The method of claim 3 , wherein the fibrotic disorder is selected from the group consisting of vascular fibrosis, pulmonary fibrosis, pancreatic fibrosis, liver fibrosis, renal fibrosis, musculoskeletal fibrosis, cardiac fibrosis, skin fibrosis, eye fibrosis, glaucoma, progressive systemic sclerosis (PSS), chronic graft versus-host disease, scleroderma, Peyronie's disease, post-cystoscopic urethral stenosis, idiopathic and pharmacologically induced retroperitoneal fibrosis, mediastinal fibrosis, progressive massive fibrosis, proliferative fibrosis and neoplastic fibrosis.

6 . The method of claim 3 further comprising administering to said subject an additional therapeutic agent.

7 . The method of claim 3 , wherein said subject is human.

8 . (canceled)

9 . The method of claim 5 , wherein the BMP9 or BMP10 antagonist is selected from the group consisting of an antibody, a small molecule, a nucleic acid, a fusion protein, an adnectin, an aptamer, an anticalin, a lipocalin, a BMP9 or BMP10-derived peptidic compound, and a receptor-based antagonist.

10 .- 15 . (canceled)

16 . A method of inhibiting the differentiation of a fibroblast to a myofibroblast, comprising contacting a fibroblast with an effective amount of a BMP9 or BMP10 antagonist, thereby inhibiting the differentiation of a fibroblast to a myofibroblast.

17 . The method of claim 16 , wherein the BMP9 or BMP10 antagonist is selected from the group consisting of an antibody, a small molecule, a nucleic acid, a fusion protein, an adnectin, an aptamer, an anticalin, a lipocalin, and a BMP9 or BMP10-derived peptidic compound.

18 .- 20 . (canceled)

21 . A method for assessing whether a subject has or is at risk of developing a fibrotic disorder comprising: (i) contacting a sample from said subject with a reagent able to detect BMP9 or BMP10; and (ii) detecting BMP9 or BMP10, wherein an elevated level of BMP9 or BMP10 relative to a control is an indication that the subject has or is at risk of developing a fibrotic disorder.

22 .- 30 . (canceled)

31 . A method of assessing the efficacy of a treatment regimen for treating a fibrotic disorder in a subject, the method comprising:
a) contacting a first sample obtained from said subject prior to administering at least a portion of the treatment regimen to the subject with a reagent able to detect BMP9 or BMP10; b) contacting a second sample obtained from said subject following administration of at least a portion of the treatment regimen with a reagent able to detect BMP9 or BMP10; and c) comparing the levels of BMP9 or BMP10 from the first and second samples, wherein an elevated level of BMP9 or BMP10 present in the first sample, relative to the second sample, is an indication that the treatment regimen is efficacious for treating a fibrotic disorder in the subject.

32 . The method of claim 31 , wherein the treatment regimen comprises administration of an BMP9 or BMP10 antagonist.

33 .- 37 . (canceled)

38 . A method of inhibiting or preventing epithelial-mesenchymal transition (EMT) in a subject comprising administering to the subject an effective amount of BMP9 or BMP10 antagonist, thereby inhibiting or preventing epithelial-mesenchymal transition (EMT).

39 . The method of claim 38 , wherein the EMT is associated with fibrosis.

40 . The method of claim 39 , wherein the fibrosis is selected from the group consisting of vascular fibrosis, pulmonary fibrosis, pancreatic fibrosis, liver fibrosis, renal fibrosis, musculoskeletal fibrosis, cardiac fibrosis, skin fibrosis, eye fibrosis, glaucoma, progressive systemic sclerosis (PSS), chronic graft versus-host disease, scleroderma, Peyronie's disease, post-cystoscopic urethral stenosis, idiopathic and pharmacologically induced retroperitoneal fibrosis, mediastinal fibrosis, progressive massive fibrosis, proliferative fibrosis and neoplastic fibrosis.

41 . The method of claim 38 , wherein the BMP9 or BMP10 antagonist is selected from the group consisting of an antibody, a small molecule, a nucleic acid, a fusion protein, an adnectin, an aptamer, an anticalin, a lipocalin, a BMP9 or BMP10-derived peptidic compound, and a receptor-based antagonist.

42 .- 47 . (canceled)

48 . A method of identifying human liver cell sample as being fibrosis comprising detecting BMP9 expression level in said cell sample with a reagent, wherein an elevated level of BMP9 relative to normal human liver cells is an indication that said liver cell sample has fibrosis.

49 . The method of claim 48 further comprising detecting an additional fibrosis marker selected from the group consisting of alpha smooth muscle actin, collagen type III cartilage oligomeric matrix protein, collagen type I, collagen type IV, fibroblast specific protein-1, fibronectin, serpinE1, periostin, IGFBP3, SPARC, CTGF, TGFb, Cyr61, and phospho smad 2/3.

50 . The method of claim 48 , wherein the reagent is an antibody or a nucleic acid.

51 . The method of claim 48 , wherein the reagent is detectably labeled.

52 . The method of claim 51 , wherein the label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, or an enzyme.

53 . The method of claim 48 , wherein the level of BMP9 is at least 2-fold higher relative to normal human liver cells.

54 . The method of claim 48 , wherein the level of BMP9 is at least 3-fold higher relative to normal human liver cells.

Assignees

• Buckler Alan
• Chen Chao-Min
• Guy Chantale T
• Hewett Jeffrey
• Lu Chris
• Wu Jing
• Novartis Ag

Inventors

• Buckler Alan
• Chen Chao-Min
• Guy Chantale T
• Hewett Jeffrey
• Lu Chris
• Wu Jing

Classifications

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61K38/1875 Primary

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• G01N33/5091

  for testing the pathological state of an organism · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title